LinkedIn Image Virtual Poster Session: Key Data on NETs Presented During the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting

Virtual Poster Session: Key Data on NETs Presented During the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting

View Activity

Activity Features

Downloadable Slides

Interactive Presentation

View Activity

Activity Overview

View slides and abstract presentations covering the most up-to-date clinical trial data of neuroendocrine tumors from the 2017 Gastrointestinal Cancer Meeting & the 2017 Annual Neuroendocrine Cancer Meeting.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Angela Lamarca, MD

Abstract #H9: PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs)
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Angela Lamarca, MD

Diego Ferone, MD, PhD

Abstract #K1: Safety and Efficacy of High Dose Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Diego Ferone, MD, PhD

Raj Srirajaskanthan, MD, MRCP

Abstract #K16: Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Raj Srirajaskanthan, MD, MRCP

Alexandria Phan, MD

Abstract #K18: Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: Alexandria Phan, MD

James C. Yao, MD

Abstract #L19: An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment
(Presented at the 2017 Annual Neuroendocrine Cancer Meeting in Barcelona)

Presented by: James C. Yao, MD

Jennifer Chan, MD, MPH

Abstract #228: Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Jennifer Chan, MD, MPH

Simron Singh, MD

Abstract #285: Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Simron Singh, MD

Jonathan Strosberg, MD

Abstract #348: Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Jonathan Strosberg, MD

George A Fisher, MD

Abstract #378: Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: George A Fisher, MD

Alexandria Phan, MD

Abstract #398: Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies
(Presented at the 2017 Gastrointestinal Cancer Meeting in San Francisco)

Presented by: Alexandria Phan, MD

Support

This educational activity is supported by IPSEN.